Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Real-World Experience With Lenacapavir and/or Fostemsavir as Emerging Therapies for the Management of Multidrug-Resistant HIV-1 in Southeastern France.

Journal of medical virology - 1 Sept 2026

Boujamline Syrine, Boschi Celine, Bes-Barlandier Hugo, Tomei Christelle, Menard Amelie, Mokhtari Saadia, Ravaux Isabelle, Belkhir Yacine, Neant Nadege, Solas Caroline, Colson Philippe, Million Matthieu

Abstract excerpt

Lenacapavir and fostemsavir, two recently approved anti-HIV-1 agents, are promising options for people with difficult-to-treat HIV; however, real-world data remain limited. This study aimed to describe the epidemiological, clinical, and virological profiles of people receiving combination antiretroviral regimens, including lenacapavir and/or fostemsavir. This retrospective study included adults living with HIV-1...

Read the complete abstract on PubMed

Topics

Humans
HIV-1
HIV Infections
France
Retrospective Studies

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Female

Middle Aged

Male

Anti-HIV Agents

Viral Load

Organophosphates

Piperazines

Drug Resistance, Multiple, Viral

Adult

Genotype

Aged

Drug Therapy, Combination

Acetamides

Source

Open in PubMed Open full text

Identifiers

PMID: 42725571
DOI: 10.1002/jmv.71149
PMCID: PMC13563682

Genes

CD4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 24 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Real-World Experience With Lenacapavir and/or Fostemsavir as Emerging Therapies for the Management of Multidrug-Resistant HIV-1 in Southeastern France.PMID 42725571Read ↗

Susceptibility to lenacapavir, fostemsavir and broadly neutralizing antibodies in French primary HIV-1 infected patients in 2020-2023.Semantic proximity Read ↗

Pretreatment drug resistance among people living with HIV from 2018 to 2022 in Guangzhou, China.Semantic proximity Read ↗

Prevalence and transmission of pretreatment drug resistance in people living with HIV-1 in Shanghai China, 2017-2021.Semantic proximity Read ↗

Prevalence and transmission of HIV-1 drug resistance mutations among patients with treatment failure and newly diagnosed people in Liangshan Prefecture, China, in 2021–2023Semantic proximity Read ↗

Virological failure and resistance emergence during treatment with bictegravir/emtricitabine/tenofovir alafenamide or dolutegravir/lamivudine in people living with HIV without prior resistance mutations: a real-world study.Semantic proximity Read ↗

Geographical and temporal trends of HIV-1 subtypes and drug resistance in China: a nationwide study over two decades (2003-2024).Semantic proximity Read ↗

Lenacapavir-associated drug resistance: implications for scaling up long-acting HIV pre-exposure prophylaxisSemantic proximity Read ↗

Drug Resistance Mutations (DRMs) for Long-Acting Injectable Cabotegravir and Rilpivirine (CAB/RPV LAI) in the HIV-1 Subtype A6 Epidemic in PolandSemantic proximity Read ↗

Emerging Trends in HIV-1 Sub-Subtype A6 in Belgium: Transmission Dynamics, Drug Resistance, and Subtyping Tool Evaluation.Semantic proximity Read ↗

Resistance Analyses in Heavily Treatment-Experienced People With HIV Treated With the Novel HIV Capsid Inhibitor Lenacapavir After 2 YearsSemantic proximity Read ↗

2022 update of the drug resistance mutations in HIV-1.Semantic proximity Read ↗

Virological Failure on Long-Acting Injectable Cabotegravir and Rilpivirine: An Analysis of Subtypes, Drug Levels, Resistance, and Therapeutic Implications.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.